Photobiomodulation shows promise as safe and tolerable adjunct therapy for Parkinson’s Disease, recent trial suggests Post author: Post published:December 5, 2023 Post category:uncategorized A safe and feasible treatment option for reducing the motor signs of Parkinson’s disease. You Might Also Like Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research April 22, 2024 Brazil achieves milestone in eliminating lymphatic filariasis October 1, 2024 FORTE accrues first 1000 participants for highly anticipated colorectal cancer prevention trial November 10, 2023
Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research April 22, 2024
FORTE accrues first 1000 participants for highly anticipated colorectal cancer prevention trial November 10, 2023